Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.09B |
| Revenue (ttm) | 19.97M |
| Net Income (ttm) | n/a |
| Shares Out | 44.35M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $27.12 |
| Previous Close | $26.17 |
| Change ($) | 0.95 |
| Change (%) | 3.63% |
| Day's Open | 25.28 |
| Day's Range | 24.63 - 27.88 |
| Day's Volume | 270,008 |
| 52-Week Range | 15.21 - 52.38 |
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands,...
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy 8 ...
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its un...
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M....
SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its un...
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced...
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies
Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix
Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies
SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be prese...
SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present d...
SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has res...
Completed recent IPO raising approximately $238 .5 million in gross proceeds
SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3...
Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally ava... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol NRIX |
Financial Performance
In 2020, NRIX's revenue was $17.82 million, a decrease of -42.73% compared to the previous year's $31.12 million. Losses were -$43.24 million, 99.3% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 49.00, which is an increase of 80.68% from the latest price.